<SEC-DOCUMENT>0001564590-19-001155.txt : 20190125
<SEC-HEADER>0001564590-19-001155.hdr.sgml : 20190125
<ACCEPTANCE-DATETIME>20190125161544
ACCESSION NUMBER:		0001564590-19-001155
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20190125
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190125
DATE AS OF CHANGE:		20190125

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		19542713

	BUSINESS ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>abio-8k_20190125.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
abio-8k_20190125.htm
</title>
</head>
<!-- NG Converter v5.0.18157.137 -->
<body>

<p style="text-align:justify;border-top:Solid 0.75pt #000000;padding-top:0pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WASHINGTON, D.C. 20549 </p>
<p style="text-align:center;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 8-K </p>
<p style="text-align:center;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT </p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported):<font style="color:#000000;font-size:12pt;"> </font><font style="color:#000000;">January 25, 2019</font></p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as Specified in Its Charter)</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:34.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="top"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">000-22873</p></td>
<td valign="top"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">36-3855489</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:34.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or Other Jurisdiction</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Incorporation)</p></td>
<td valign="bottom"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission File Number)</p></td>
<td valign="bottom"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr>
<td valign="top"  style="width:34.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:34.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11080 CirclePoint Road, Suite 140, Westminster, CO</p></td>
<td valign="bottom"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">80020</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:34.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of Principal Executive Offices)</p></td>
<td valign="bottom"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s Telephone Number, Including Area Code: (720) 940-2200</p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Not Applicable </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Former Name or Former Address, if Changed Since Last Report) </p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below): </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:9pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:9pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:9pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:9pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </p></td></tr></table></div>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&#160;<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font></p>
<p style="text-align:justify;margin-top:4pt;border-top:Solid 0.75pt #000000;padding-top:0pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-top:2pt;border-top:Solid 1pt;padding-top:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><a name="P280769376"></a>Item 1.01</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Entry Into a Material Definitive Agreement.</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 25, 2019, ARCA biopharma, Inc. (the &#8220;Company&#8221;) entered into Amendment No. 2 (the &#8220;Amendment&#8221;) to its Capital on Demand<sup style="font-size:85%; vertical-align:top">TM</sup> Sales Agreement, dated as of January 11, 2017, as amended by the Amendment No. 1, dated as of August 21, 2017, (together, the &#8220;Sales Agreement&#8221; and, as amended by the Amendment, the &#8220;Amended Sales Agreement&#8221;), with JonesTrading Institutional Services LLC, as agent (&#8220;Agent&#8221;). The Amendment, among other things, increased the maximum aggregate offering value of shares of the Company&#8217;s common stock (the &#8220;Additional Shares&#8221;) which the Company may issue and sell from time to time under the Amended Sales Agreement (the &#8220;Offering&#8221;) by approximately $2.5&#160;million, from $10,242,863 to $12,742,739.&nbsp;&nbsp;As of January 25, 2019, the Company had sold 4,811,353 shares of its common stock under the Sales Agreement for an aggregate offering price of $10,083,445, before deducting sales and commissions and offering expenses. The Company will file a prospectus supplement with the Securities and Exchange Commission (the &#8220;SEC&#8221;) in connection with the Offering (the &#8220;Prospectus Supplement&#8221;) under its existing Registration Statement on Form S-3 (File No 333-217459), which became effective on May 12, 2017 (the &#8220;Registration Statement&#8221;).</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="S116575981"></a>Under the Amended Sales Agreement, Agent may sell the Additional Shares by any method permitted by law and deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415 promulgated under the Securities Act of 1933, as amended. The Company may instruct Agent not to sell Additional Shares if the sales cannot be effected at or above the price designated by the Company from time to time.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is not obligated to make any sales of the Additional Shares under the Amended Sales Agreement. The Offering will terminate upon the earlier of (a) the sale of all of the Additional Shares subject to the Amended Sales Agreement or (b) the termination of the Amended Sales Agreement by Agent or the Company, as permitted therein.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will pay Agent a commission rate equal to 3.0% of the aggregate gross proceeds from each sale of Additional Shares and has agreed to provide Agent with customary indemnification and contribution rights. The Company will also reimburse Agent for certain specified expenses in connection with entering into the Amended Sales Agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The foregoing description of the Amended Sales Agreement is not complete and is qualified in its entirety by reference to the full text of such agreement, a copy of which is filed herewith as Exhibit 10.1 to this Current Report on Form&#160;8-K&#160;and is incorporated herein by reference. The Company previously filed the Sales Agreement as Exhibit 10.1 to its Current Report on Form 8-K filed with the SEC on January 11, 2017 and the Amendment No.1 as Exhibit 10.1 to its Current Report on Form 8-K filed with the SEC on August&#160;21,&#160;2017. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cooley LLP, counsel to the Company, has issued a legal opinion relating to the Additional Shares. A copy of such legal opinion, including the consent included therein, is attached as Exhibit 5.1 hereto.</p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Additional Shares will be sold pursuant to the Registration Statement, and offerings of the Additional Shares will be made only by means of the Prospectus Supplement and any accompanying prospectus. This Current Report on Form 8-K shall not constitute an offer to sell or solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of such state or jurisdiction<font style="color:#000000;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Section&#160;8 &#8212; Other Events</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.01.</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> Other Events. </p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is seeking a Special Protocol Assessment (&#8220;SPA&#8221;) agreement with the U.S. Food and Drug Administration (the &#8220;FDA&#8221;).&nbsp;&nbsp;<font style="color:#000000;">The FDA&#8217;s SPA process is designed to facilitate the FDA&#8217;s review and approval of drugs by allowing FDA to evaluate the proposed design and size of certain clinical trials that are intended to form the primary basis for determining a drug product&#8217;s efficacy and safety. Upon specific request by a clinical trial sponsor, the FDA will evaluate the protocol and respond to a sponsor&#8217;s questions regarding, among other things, primary efficacy endpoints, trial conduct and data analysis, within 45 days of receipt of the request.&nbsp;&nbsp;The FDA ultimately assesses whether the protocol design and planned analysis of the trial are acceptable to support regulatory approval of the product candidate for the indication studied.&nbsp;&nbsp;An SPA agreement can potentially reduce the regulatory risk of bringing a drug to market.</font> </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><a name="_Hlk528921723"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company submitted an SPA request to the FDA in September 2018. In late October 2018</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk528921723"></a>, the Company received a No Agreement letter from the FDA on its SPA</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> request.&nbsp;&nbsp;After further correspondence and following provision of information regarding the SPA, the Company met with the FDA in December 2018 and the FDA agreed to reconsider the Company</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;s SPA request.&nbsp;&nbsp;In December 2018, the Company submitted an amendment to the original SPA request that addressed the feedback and guidance from the FDA on the target population for the Company&#8217;s planned Phase 3 clinical trial.&nbsp;&nbsp;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2019, the Company</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> received a No Agreement letter in response to the SPA amendment.&nbsp;&nbsp;In January 2019, addressing the FDA&#8217;s new guidance, the Company refined the design and statistical power for the Company&#8217;s planned Phase 3 clinical trial and resubmitted its SPA request to </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the FDA</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="margin-bottom:16pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk535583399"></a><a name="_Hlk535583556"></a>The Company&#8217;s SPA request, as resubmitted, details a single adequate and well-controlled Phase 3 clinical trial (PRECISION-AF) designed as a double-blind, active-controlled, multicenter, international, study comparing Gencaro with TOPROL-XL (meto<a name="_Hlk535583399"></a><a name="_Hlk535583556"></a>prolol succinate) for the prevention of recurrent atrial fibrillation (&#8220;AF&#8221;) or all-cause mortality (&#8220;ACM&#8221;), in patients with chronic heart failure and a mid-range left ventricular ejection fraction (LVEF) &#8805; 0.40 and &lt;&#160;0.50 (&#8220;HFmrEF&#8221;).&nbsp;&nbsp;Eligible patients will have HFmrEF, a recent AF event and the genotype which responds most favorably to Gencaro.  The primary endpoint of the submitted trial will be time to first event of atrial fibrillation/atrial flutter or ACM during a 26-week follow-up period.&nbsp;&nbsp;Subject to the FDA&#8217;s approval of the Company&#8217;s SPA request and securing significant additional financing, the Company anticipates initiating PRECISION-AF in the fourth quarter of 2019. The Company expects to receive the FDA&#8217;s response to the Company&#8217;s SPA request in February 2019.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Caution Concerning Forward Looking Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Current Report on Form 8-K may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act and Section 21 E of the Exchange Act.&#160;&#160;These statements include, but are not limited to, statements regarding potential Phase 3 development plans for Gencaro, the timing and results of any clinical trials, including PRECISION-AF, any potential future PRECISION-AF trials, <font style="color:#000000;">the Company&#8217;s requested SPA from the FDA relating to the Company&#8217;s planned Phase 3 program for&#160;Gencaro, </font>the expected features and characteristics of Gencaro, including the potential for genetic variations to predict individual patient response to Gencaro, Gencaro&#8217;s potential to treat AF, future treatment options for patients with AF, the potential for Gencaro to be the first genetically-targeted AF prevention treatment and the ability of ARCA&#8217;s financial resources to support its operations through the first quarter of 2019.&nbsp;&nbsp;Such statements are based on management's current expectations and involve risks and uncertainties.&nbsp;&nbsp;Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: ARCA&#8217;s financial resources and whether they will be sufficient to meet its business objectives and operational requirements; ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or to otherwise continue operations in the future; results of earlier clinical trials may not be confirmed in future trials; the protection and market exclusivity provided by ARCA&#8217;s intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes.&nbsp;&nbsp;These and other factors are identified and described in more detail in ARCA&#8217;s filings with the Securities and Exchange Commission, including without limitation ARCA&#8217;s annual report on Form 10-K for the year ended December 31, 2017, and subsequent filings. ARCA disclaims any intent or obligation to update these forward-looking statements.</p>
<p style="margin-top:13pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Section 9 &#8212; Financial Statements and Exhibits </p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 9.01. Financial Statements and Exhibits. </p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) Exhibits. </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:87.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;white-space:nowrap;">
<p style="text-align:center;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit Number</p></td>
<td valign="bottom"  style="width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:87.5%;white-space:nowrap;">
<p style="border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1</p></td>
<td valign="bottom"  style="width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:87.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="abio-ex51_29.htm"><font style="text-decoration:underline;">Opinion of Cooley LLP</font></a>.</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="bottom"  style="width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:87.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="abio-ex101_8.htm"><font style="text-decoration:underline;">Amendment No. 2 to Capital on Demand</font><font style="font-size:8.5pt;text-decoration:underline;"><sup style="font-size:85%; vertical-align:top">TM</sup></font><font style="text-decoration:underline;">&#160;Sales Agreement, dated January 25, 2019, by and between ARCA biopharma, Inc. and JonesTrading Institutional Services LLC</font></a>.</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.1</p></td>
<td valign="bottom"  style="width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:87.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="abio-ex51_29.htm"><font style="text-decoration:underline;">Consent of Cooley LLP (included in Exhibit 5.1).</font></a></p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:62.25%;"></td>
<td style="width:4.17%;"></td>
<td style="width:5.5%;"></td>
<td style="width:28.08%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: January 25, 2019</p></td>
<td colspan="3" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="3" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc.</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Registrant)</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td colspan="2" valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Brian L. Selby</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brian L. Selby</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vice President, Finance and Chief Accounting Officer</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>abio-ex51_29.htm
<DESCRIPTION>EX-5.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
abio-ex51_29.htm
</title>
</head>
<!-- NG Converter v5.0.18157.137 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 5.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gnkjkiq1er20000001.jpg" title="" alt="" style="width:136px;height:44px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:45.38%;">
<p style="margin-bottom:0pt;line-height:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:0.1pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brent D. Fassett</p>
<p style="margin-bottom:0pt;line-height:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+1 720 566 4025</p>
<p style="margin-bottom:0pt;line-height:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bfassett@cooley.com</p>
<p style="margin-bottom:0pt;line-height:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:54.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 25, 2019</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc.<br />11080 CirclePoint Road, Suite 140<br />Westminster, CO 80020</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M7"></a><a name="_DV_M7"></a>Ladies and Gentlemen:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M12"></a><a name="_DV_M17"></a><a name="_DV_M15"></a><a name="_DV_M16"></a>You have requested our opinion, as counsel to ARCA biopharma, Inc.<font style="color:#000000;">, a Delaware corporation (the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Company</font><font style="color:#000000;">&#8221;), with respect to certain matters in connection with the offering by the Company of the $2,499,876 of the Company&#8217;s common stock, par value $0.001 (the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Shares</font><font style="color:#000000;">&#8221;), pursuant to a<a name="_DV_M12"></a> Registration Statement on Form S-3 (No. 333-217459) (the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Registration Statement</font><font style="color:#000000;"><a name="_DV_M17"></a>&#8221;), <a name="_DV_M15"></a>filed with the Securities and Exchange Commission (the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Commission</font><font style="color:#000000;">&#8221;<a name="_DV_M16"></a>) under the Securities Act of 1933, as amended (the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Act</font><font style="color:#000000;">&#8221;), the prospectus included within the Registration Statement (the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Base Prospectus</font><font style="color:#000000;">&#8221;), and the prospectus supplement dated January 25, 2019, filed with the Commission pursuant to Rule 424(b) of the Rules and Regulations of the Act (together with the Base Prospectus, the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Prospectus</font><font style="color:#000000;">&#8221;) The Shares are to be sold by the Company in accordance with a Capital on Demand&#8482;</font><font style="font-weight:bold;color:#000000;"> </font>Sales Agreement, dated January 11, 2017 and as amended on August 21, 2017 and January 25, 2019, between the Company and JonesTrading Institutional Services LLC (the &#8220;<font style="font-weight:bold;font-style:italic;">Agreement</font>&#8221;)<font style="color:#000000;">, as described in the Prospectus.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with this opinion, we have examined and relied upon the Registration Statement and the Prospectus, the Agreement, the Company&#8217;s Amended and Restated Certificate of Incorporation, as amended, and Second Amended and Restated Bylaws, as amended, and the originals or copies certified to our satisfaction of such records, documents, certificates, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. In rendering this opinion, we have assumed the genuineness and authenticity of all signatures on original documents; the genuineness and authenticity of all documents submitted to us as originals; the conformity to originals of all documents submitted to us as copies; and the accuracy, completeness and authenticity of certificates of public officials.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have assumed (i) that each sale of Shares will be duly authorized by the Board of Directors of the Company, a duly authorized committee thereof or a person or body pursuant to an authorization granted in accordance with Section 152 of the General Corporation Law of the State of Delaware (the &#8220;<font style="font-weight:bold;font-style:italic;">DGCL</font>&#8221;), (ii) that no more than 25,000,000 Shares will be sold under the Agreement and (iii) that the price at which the Shares are sold will equal or exceed the par value of the Shares.&nbsp;&nbsp;We express no opinion to the extent that future issuances of securities of the Company and/or anti-dilution adjustments to outstanding securities of the Company cause the number of shares of the Company&#8217;s common stock outstanding or issuable upon conversion or exercise of outstanding securities of the Company to exceed the number of Shares then issuable under the Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our opinion herein is expressed solely with respect to the DGCL.&nbsp;&nbsp;Our opinion is based on these laws as in effect on the date hereof.&nbsp;&nbsp;We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation. </p>
<p style="margin-top:12pt;text-align:center;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="zzmpFIXED_LHFirstPageFooter_Text"></a><a name="zzmpFIXED_LHFirstPageFooter_Text"></a> Cooley LLP&nbsp;&nbsp; 380 Interlocken Crescent&nbsp;&nbsp; Suite 900&nbsp;&nbsp; Broomfield, CO&nbsp;&nbsp; 80021-8023<br />t: (720) 566-4000&nbsp;&nbsp;f: (720) 566-4099&nbsp;&nbsp;cooley.com</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:3.45pt;">
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gnkjkiq1er20000001.jpg" title="" alt="" style="width:136px;height:44px;"></p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&nbsp;</p></td>
</tr>
<tr style="height:3.45pt;">
<td valign="bottom"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&nbsp;</p></td>
</tr>
<tr style="height:26pt;">
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 25, 2019</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page Two</p></td>
<td valign="top"  style="width:50%;">
<p style="text-align:right;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:bold;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:1.15%;margin-right:1.07%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On the basis of the foregoing, and in reliance thereon, we are</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of the opinion that the Shares, </font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">when sold and issued against payment therefor in accordance with the Agreement, the Registration Statement and the Prospectus, will be validly issued, fully paid and non</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">assessable.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consent to the reference to our firm under the caption &#8220;<font style="font-weight:bold;">Legal Matters</font>&#8221; in the Prospectus and to the filing of this opinion as an exhibit to the Company&#8217;s Current Report on Form 8-K to be filed with the Commission for incorporation by reference into the Registration Statement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Very truly yours,</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;">Cooley LLP</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:23.08%;">
<tr>
<td valign="top"  style="width:13.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td colspan="2" valign="top"  style="width:86.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> /s/ Brent D. Fassett</p></td>
</tr>
<tr>
<td valign="top"  style="width:13.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:15.5%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:71.12%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brent D. Fassett</p></td>
</tr>
</table></div>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:center;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cooley LLP&nbsp;&nbsp; 380 Interlocken Crescent&nbsp;&nbsp; Suite 900&nbsp;&nbsp; Broomfield, CO&nbsp;&nbsp; 80021-8023<br />t: (720) 566-4000&nbsp;&nbsp;f: (720) 566-4099&nbsp;&nbsp;cooley.com</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>abio-ex101_8.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
abio-ex101_8.htm
</title>
</head>
<!-- NG Converter v5.0.18157.137 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.1</p>
<p style="margin-bottom:5pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;text-transform:uppercase;">&nbsp;</p>
<p style="margin-bottom:5pt;text-align:center;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;"><br />AMENDMENT NO. 2 TO Capital on Demand&#8482; SALES AGREEMENT<br /></font></p>
<p style="text-align:right;margin-bottom:5pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">January 25, 2019</font></p>
<p style="margin-bottom:5pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;text-transform:uppercase;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JonesTrading Institutional Services LLC</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">757 Third Avenue, 23<sup style="font-size:85%; vertical-align:top">rd</sup> Floor</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New York, NY 10017</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ladies and Gentlemen:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc., a Delaware corporation (the &#8220;<font style="text-decoration:underline;">Company</font>&#8221;), and JonesTrading Institutional Services LLC (the &#8220;<font style="text-decoration:underline;">Agent</font>&#8221;), are parties to that certain Capital on Demand&#8482; Sales Agreement<font style="font-weight:bold;"> </font>dated January 11, 2017, as amended on August 21, 2017 (together, the &#8220;<font style="text-decoration:underline;">Original</font><font style="font-weight:bold;text-decoration:underline;"> </font><font style="text-decoration:underline;">Agreement</font>&#8221;). All capitalized terms not defined herein shall have the meanings ascribed to them in the Original Agreement.&nbsp;&nbsp;The parties, intending to be legally bound, hereby amend the Original Agreement pursuant to the terms of this amendment No. 2 to the Original Agreement (this &#8220;<font style="text-decoration:underline;">Amendment No. 2</font>&#8221;) as follows:</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;"></font>The first and second paragraphs of Section 1 of the Original Agreement are hereby deleted in their entirety and replaced with the following<font style="color:#0000FF;">:</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>&#8220;<font style="text-decoration:underline;">Issuance and Sale of Shares</font>.&nbsp;&nbsp;The Company agrees that, from time to time during the term of this Agreement, on the terms and subject to the conditions set forth herein, it may issue and sell through or to the Agent, as sales agent or principal, shares (the &#8220;<font style="text-decoration:underline;">Placement Shares</font>&#8221;) of common stock of the Company, $0.001 par value per share (the &#8220;<font style="text-decoration:underline;">Common Stock</font>&#8221;) having an aggregate offering price of up to $12,742,739, provided, however, that in no event shall the Company issue or sell through Agent such number of Placement Shares that (a) exceeds the number or dollar amount of shares of Common Stock that may be sold pursuant to the Registration Statement (as defined below), or (b) exceeds the number of authorized but unissued shares of Common Stock of the Company (the &#8220;<font style="text-decoration:underline;">Maximum Amount</font>&#8221;). Pursuant to this Agreement, shares of our common stock were previously sold for $10,083,445 in aggregate gross proceeds under a separate prospectus and prospectus supplement. Under this Agreement, as amended by Amendment No. 1 to Capital on Demand&#8482; Sales Agreement, dated August 21, 2017, and as further amended by Amendment No. 2 to Capital on Demand&#8482; Sales Agreement, dated January 25, 2019, the Company, through the Agent, may offer and sell further shares of common stock having an aggregate offering price of up to $2,659,294 pursuant to the Prospectus (as defined below).&nbsp;&nbsp;Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitations set forth in this Section 1 on the amount of Placement Shares issued and sold under this Agreement shall be the sole responsibility of the Company and that Agent shall have no obligation in connection with such compliance. The issuance and sale of Placement Shares through Agent will be effected pursuant to the Registration Statement (as defined below) filed by the Company and at no earlier time than such time as the Registration Statement shall </p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:normal;font-size:8pt;font-family:Arial;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">DM3\5586754.4</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;margin-left:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have been declared effective by the Securities and Exchange Commission (the &#8220;</font><font style="text-decoration:underline;">Commission</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;), although nothing in this Agreement shall be construed as requiring the Company to use the Registration Statement to issue Placement Shares.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of the date hereof, the Company has filed Form S-3 (333-217459) (the &#8220;<font style="text-decoration:underline;">Current Registration Statement</font>&#8221;), or will file a registration statement on Form S-3, in accordance with the provisions of the Securities Act of 1933, as amended (the &#8220;<font style="text-decoration:underline;">Securities Act</font>&#8221;) and the rules and regulations thereunder (the &#8220;<font style="text-decoration:underline;">Securities Act Regulations</font>&#8221;), with the Commission, including a base prospectus, relating to certain securities, including the Placement Shares to be issued from time to time by the Company, and which incorporates by reference documents that the Company has filed or will file in accordance with the provisions of the Securities Exchange Act of 1934, as amended (the &#8220;<font style="text-decoration:underline;">Exchange Act</font>&#8221;), and the rules and regulations thereunder (the &#8220;<font style="text-decoration:underline;">Exchange Act Regulations</font>&#8221;).&nbsp;&nbsp;The Company has prepared a prospectus supplement specifically relating to the Placement Shares (the &#8220;<font style="text-decoration:underline;">Prospectus Supplement</font>&#8221;) to the base prospectus included as part of such registration statement.&nbsp;&nbsp;The Company will furnish to <font style="color:#000000;">the Agent</font>, for use by t<font style="color:#000000;">he Agent</font>, copies of the prospectus included as part of such registration statement, as supplemented by the Prospectus Supplement, relating to the Placement Shares.&nbsp;&nbsp;Except where the context otherwise requires, such registration statement, and any post-effective amendment thereto, including all documents filed as part thereof or incorporated by reference therein, and including any information contained in a Prospectus (as defined below) subsequently filed with the Commission pursuant to Rule&#160;424(b) under the Securities Act Regulations or deemed to be a part of such registration statement pursuant to Rule&#160;430B of the Securities Act Regulations or any subsequent registration statement on Form S-3 filed pursuant to Rule 415(a)(6) under the Securities Act by the Company to cover any securities registered pursuant the Current Registration Statement, including any Placement Shares, as a result of the end of the three-year period described in Rule 415(a)(5) of the Securities Act, is herein called the &#8220;<font style="text-decoration:underline;">Registration Statement</font>.&#8221;&nbsp;&nbsp;The base prospectus, including all documents incorporated therein by reference, included in the Registration Statement, as it may be supplemented by the Prospectus Supplement, in the form in which such prospectus and/or Prospectus Supplement have most recently been filed by the Company with the Commission pursuant to Rule&#160;424(b) under the Securities Act Regulations, together with any then issued Issuer Free Writing Prospectus (defined below), is herein called the &#8220;<font style="text-decoration:underline;">Prospectus</font>.&#8221;<font style="font-weight:bold;">&nbsp;&nbsp;</font>Any reference herein to the Registration Statement, the Prospectus or any amendment or supplement thereto shall be deemed to refer to and include the documents incorporated by reference therein, and any reference herein to the terms &#8220;amend,&#8221; &#8220;amendment&#8221; or &#8220;supplement&#8221; with respect to the Registration Statement or the Prospectus shall be deemed to refer to and include the filing after the execution hereof of any document with the Commission deemed to be incorporated by reference therein.&#8221;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;"></font>Section 3 of the Original Agreement is hereby deleted in its entirety and replaced with the following<font style="color:#0000FF;">:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Sale of Placement Shares by Agent</font>. Subject to the provisions of <font style="text-decoration:underline;">Section 5(a)</font>, the</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>Agent, for the period specified in the Placement Notice, will use its commercially reasonable efforts consistent with its normal trading and sales practices and applicable </p>
<p style="text-align:center;margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">state and federal laws, rules and regulations and the rules of The NASDAQ Stock Market LLC (the &#8220;</font><font style="text-decoration:underline;">Exchange</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;), to sell the Placement Shares up to the amount specified, and otherwise in accordance with the terms of such Placement Notice. The Agent will provide written confirmation to the Company no later than the opening of the Trading Day (as defined below) immediately following the Trading Day on which it has made sales of Placement Shares hereunder setting forth the number of Placement Shares sold on such day, the compensation payable by the Company to the Agent pursuant to </font><font style="text-decoration:underline;">Section 2</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> with respect to such sales, and the Net Proceeds (as defined below) payable to the Company, with an itemization of the deductions made by the Agent (as set forth in </font><font style="text-decoration:underline;">Section 5(b))</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> from the gross proceeds that it receives from such sales. Subject to the terms of the Placement Notice, the Agent may sell Placement Shares by any method permitted by law deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) of the Securities Act Regulations.&#8221;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:12pt;text-align:justify;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:36pt;"></font>Section 5(b) of the Original Agreement is hereby deleted in its entirety and replaced with the following:</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Settlement of Placement Shares</font><font style="font-style:italic;">. </font> Unless otherwise specified in the applicable Placement Notice, settlement for sales of Placement Shares will occur on the second (2<sup style="font-size:85%; vertical-align:top">nd</sup>) Trading Day (or such earlier day as is industry practice for regular-way trading) following the date on which such sales are made (each, a &#8220;<font style="text-decoration:underline;">Settlement Date</font>&#8221;).&nbsp;&nbsp;The amount of proceeds to be delivered to the Company on a Settlement Date against receipt of the Placement Shares sold (the &#8220;<font style="text-decoration:underline;">Net Proceeds</font>&#8221;) will be equal to the aggregate sales price received by the Agent, after deduction for (i) the Agent&#8217;s commission, discount or other compensation for such sales payable by the Company pursuant to Section 2 hereof, and (ii) any transaction fees imposed by any governmental or self-regulatory organization in respect of such sales.&#8221;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="margin-left:36pt;"></font>Section 6(s) of the Original Agreement is hereby deleted in its entirety and replaced with the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">&#8220;Market Capitalization</font>.&nbsp;&nbsp;The aggregate market value&#160;of the outstanding voting and non-voting common equity (as defined in Securities Act Rule 405) of the Company held by persons other than affiliates of the Company (pursuant to Securities Act Rule 144, those that directly, or indirectly through one or more intermediaries, control, or are controlled by, or are under common control with, the Company)&#160; (the &#8220;<font style="font-weight:bold;text-decoration:underline;">Non-Affiliate Shares</font>&#8221;), was equal to $7,499,629 million&#160; (calculated by multiplying (x) the highest price at which the common equity of the Company closed on the Exchange within 60 days of the date of Amendment No. 2 to Capital on Demand&#8482; Sales Agreement times (y) the number of Non-Affiliate Shares).&nbsp;&nbsp;The Company is not a shell company (as defined in Rule 405 under the Securities Act) and has not been a shell company for at least 12 calendar months previously and if it has been a shell company at any time previously, has filed current Form 10 information (as defined in Instruction I.B.6 of Form S-3) with the Commission at least 12 calendar months previously reflecting its status as an entity that is not a shell company.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font><font style="margin-left:36pt;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 8 of the Original Agreement is hereby deleted in its entirety and replaced with the following</font><font style="color:#0000FF;">:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Payment of Expenses</font>. The Company will pay all expenses incident to the performance of its obligations under this Agreement, including (i) the preparation, filing, including any fees required by the Commission, and printing of the Registration Statement including financial statements and exhibits) as originally filed and of each amendment and supplement thereto, in such number as the Agent shall reasonably deem necessary, (ii) the printing and delivery to the Agent of this Agreement and such other documents as may be required in connection with the offering, purchase, sale, issuance or delivery of the Placement Shares, (iii) the fees and disbursements of the counsel, accountants and other advisors to the Company, (iv) the reasonable and documented out-of-pocket expenses of Agent, including reasonable and documented fees and disbursements of counsel to the Agent, (v) the printing and delivery to the Agent of copies of any Permitted Issuer Free Writing Prospectus (defined below) and the Prospectus and any amendments or supplements thereto in such number as the Agent shall deem reasonably necessary, (vi) the preparation, printing and delivery to the Agent of copies of the blue sky survey and any Canadian &#8220;wrapper&#8221; and any supplements thereto, in such number as the Agent shall deem reasonably necessary, (vii) the documented fees and expenses of the transfer agent and registrar for the Common Stock, (viii) the reasonable and documented fees and expenses incident to any review by FINRA of the terms of the sale of the Placement Shares, including fees and expenses of counsel to the Agent, and (ix) the documented fees and expenses incurred in connection with the listing of the Placement Shares on the Exchange. Notwithstanding the foregoing, in no event shall the amount of expenses reimbursed to Agent hereunder exceed $65,000, further the parties hereto agree that, as of the effective date of Amendment No. 2 to Capital on Demand&#8482; Sales Agreement, the Company has reimbursed $38,000 of such expenses to Agent.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.<font style="margin-left:36pt;"></font>Section 13 is hereby amended to replace the notice party information of JonesTrading Institutional Services LLC and Duane Morris, LLP as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;JonesTrading Institutional Services LLC</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">900 Island Park Drive, Suite 160</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Daniel Island, SC 29492</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attn: Burke Cook</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">And</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Duane Morris, LLP</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1540 Broadway</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New York, NY 10036<font style="margin-left:36pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attn:&nbsp;&nbsp;Dean M. Colucci</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facsimile: (973) 556-1406&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a>7.<font style="margin-left:36pt;"></font>All references to &#8220;January 11, 2017 (as amended by Amendment No. 1 to Capital on Demand&#8482; Sales Agreement, dated August 21, 2017)&#8221; set forth in Schedule I and Exhibit 7(l) </p>
<p style="text-align:center;margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the Original Agreement are revised to read &#8220;January 11, 2017 (as amended by Amendment No. 1 to </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capital on Demand&#8482; </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales Agreement, dated August 21, 2017 and as further amended by Amendment No. 2 to </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capital on Demand&#8482; </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales Agreement, dated January 25</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2019)&#8221;.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.<font style="margin-left:36pt;"></font>Except as specifically set forth herein, all other provisions of the Original Agreement shall remain in full force and effect.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.<font style="margin-left:36pt;"></font>This Amendment No. 2 together with the Original Agreement (including all schedules and exhibits attached hereto and thereto and Placement Notices issued pursuant hereto and thereto) constitutes the entire agreement and supersedes all other prior and contemporaneous agreements and undertakings, both written and oral, among the parties hereto with regard to the subject matter hereof. All references in the Original Agreement to the &#8220;Agreement&#8221; shall mean the Original Agreement as amended by this Amendment No. 2; <font style="font-style:italic;">provided, however</font>, that all references to &#8220;date of this Agreement&#8221; in the Original Agreement shall continue to refer to the date of the Original Agreement.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.<font style="margin-left:36pt;"></font>This Amendment shall be governed by, and construed in accordance with, the internal laws of the State of New York without regard to the principles of conflicts of laws. <font style="letter-spacing:-0.15pt;">Each party hereby irrevocably submits to the non-exclusive jurisdiction of the state and federal courts sitting in the City of New York, borough of Manhattan, for the adjudication of any dispute hereunder or in connection with any transaction contemplated hereby, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper.&nbsp;&nbsp;Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof (certified or registered mail, return receipt requested) to such party at the address in effect for notices to it under this Amendment and agrees that such service shall constitute good and sufficient service of process and notice thereof.&nbsp;&nbsp;Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.<font style="margin-left:36pt;"></font>The Company and the Agent each hereby irrevocably waives any right it may have to a trial by jury in respect of any claim based upon or arising out of this amendment or any transaction contemplated hereby.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.<font style="margin-left:36pt;"></font>This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Delivery of an executed amendment by one party to the other may be made by facsimile transmission.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[Remainder of Page Intentionally Blank]</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the foregoing correctly sets forth the understanding among the Company and the Agent, please so indicate in the space provided below for that purpose, whereupon this letter shall constitute a binding amendment to the Agreement between the Company and the Agent.&nbsp;&nbsp;</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Very truly yours,</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">JONESTRADING INSTITUTIONAL SERVICES LLC</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:&#160;&nbsp;&nbsp;&nbsp;&nbsp; <font style="text-decoration:underline;">_/s/ Burke Cook</font>_____________</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:&nbsp;&nbsp;Burke Cook</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:&nbsp;&nbsp;<font style="margin-left:36pt;">General Counsel</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ACCEPTED as of the date</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">first-above written:</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARCA BIOPHARMA, INC.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:&nbsp;&nbsp;&nbsp;&nbsp;<font style="text-decoration:underline;">_/s/ Brian Selby</font>______________</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:&nbsp;&nbsp;Brian Selby</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:&nbsp;&nbsp;Vice President, Finance</p>
<p style="text-align:right;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:8pt;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">[</font><font style="font-style:italic;text-decoration:none;">Signature Page to Amendment No. 2</font><font style="text-decoration:none;">]</font></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>gnkjkiq1er20000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gnkjkiq1er20000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %3! T# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%,EECAB>65UCC12SNYP% ZDGL*
M W'URGB3Q]I.@*\4;K>WRMM-O$_"\D'<V"%(P>.O3C'-<5XM^)-QJ&^QT1I+
M6V5^;I6*R2@8QCH4&<^Y&.G(KSZN6IB+:1/J<NX?<DJF*T\O\_\ +?T-[7?&
M.M>(<I=W.RV/_+M "D?;J.K<@'YB<'IBL&BBN5MMW9]72HTZ,>2FK+R"BBBD
M:!1110 4444 %%%% !1110 4444 =#X=\9:MX=EC6&=IK)6^>TD;*$<Y"_W#
MR3D=\9STKV+PUXMTWQ- /LS^7=J@>:V?[R<XX/1AGN/49P3BOGRG12R0RI+$
M[1R(P9'0X*D="#V-:TZTH:=#R,PR>ABUS+W9]U^O?\SZ?HKE/A]KE]K_ (=D
MN-1D62>*X:+S @4L,*PR!QGYL< =!75UWQDI*Z/A,10E0JRI3W04444S$***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** .7^(O_ "(FI?\ ;+_T:E>#5[S\1?\ D1-2_P"V7_HU*\&KBQ/Q
MGV_#7^Z2_P 3_)!1117.?0A7T;X:_P"15T?_ *\H?_0!7SE7T;X:_P"15T?_
M *\H?_0!73AMV?,<3?PJ?J_R-2BBBNP^."BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8^QRS/(8EJE55I_@_P#)_P!>1V'PE_Y%6Z_Z_7_] 2N\K@_A+_R*MU_U^O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOY1+>W4]S(%VAYI"Y ],GMR?SJO6+Q/9'KPX87VZGW+_ (/Z'T;_ ,)+H/\
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MOEZKNG:MJ.DR^9I][/;,65F$;D!B.FX=&'7@YZFFL3W1C5X8TO3J?>OU_P"
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M8G?8^/E&4).,E9H****"0HHHH **** "BBF2RQPQ/+*ZQQHI9W<X"@=23V%
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MW4_>*C+-R2-S'DXR<9/%7ZZXX9?:/E<3Q+5D[4(V7GJ_\E^)Y=_PI[_J._\
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M%<W,5G:374[[(84:21L$X4#).!STKYRUK59=;UFZU*8;6G?<%X.U>BKD 9P
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M%%%%!0Z**2:5(HD:21V"HB#)8GH .YKVCP7X"@T6!;W5(HY]2?#!6 9;?!R
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M;XEH<U"-7^5V^_\ X8[6BBBNT^+"O ?'>H?VCXSU%PTACA?R%60_=V#:P'/
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MTX!W)W[>PKRFBKIRY97./'85XJ@Z*ERWZVO_ )'U#17R]16_UKR/G_\ 5?\
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M%+.[G 4#J2>PKYAKDQ70^LX77\5^GZA1117*?6!1110 4444 %%%% !1110
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M444 %%%% !1110 4444 %%%% !1110 5R_Q%_P"1$U+_ +9?^C4KJ*R_$O\
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M5\5^,;WQ3.@=/L]G%S';*^X;L<LQP,GKCC@?B3E4JJ"\SU<MRJKC))[0ZO\
MR_K0]@\*>(_^$GL;N]6'R84NFAA4_>*!5.6[9))Z=.G/4[U<'\)?^15NO^OU
M_P#T!*[RJIMN*;.;,*4*.*G3@K),****LXSYPU_2VT77[W3B&"P2D)O8$E#R
MI)'&2I!_&LVO1OBUI7DZE9ZK&F%G0PRE8\#>O(+-W)!P,]D_+SFO-J1Y9-'Z
M9E^(^L8:%7JUKZ]0HHHJ#L.R^&VN_P!D^)%M)6Q;:AB%N.DG\!Z$]25[#YLG
MI7M]?+U>[>!_%D?B/2UBN)E_M2!?WZ;=N\9X<#N.F<=#V (KKP]3[+/DN(L
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MDB!QC'4N,Y]P,=>37GU<,H.+LS[O"XNCBH>TI.Z_+U"BBBI.D**** "BBB@
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M2LC\_J5)5)N<W=L****9 4444 <O\1?^1$U+_ME_Z-2O!J]Y^(O_ "(FI?\
M;+_T:E>#5Q8GXS[?AK_=)?XG^2"BBBN<^A"OHWPU_P BKH__ %Y0_P#H KYR
MKZ-\-?\ (JZ/_P!>4/\ Z *Z<-NSYCB;^%3]7^1J4445V'QP4444 07ME;:C
M92V=Y"LUO*NUT;H1_0]P>U> ^*?#=SX:U>2VD1OLSL6MI2<ATSQS@?,.,C^A
M!/T+6-XE\-67B;33:W0V2IDP3J,M$W]0>X[^Q (RJT^=:;GKY1F3P=6TO@>_
M^?\ 70^=Z*U-<\/:EX=NU@U&#9OR8Y%.Y) #C(/Y<'!&1D#-9=>>TT[,^^IU
M(5(J<'=,****"PK4T[Q)K6D^6+'4[F*.+.R+>6C&<Y^0Y7N3TZ\UET4)M;$3
MIPJ+EFKKS.WMOBIXA@@6.1+*X89S++$0S<]]K >W J7_ (6UKW_/IIO_ '[?
M_P"+K@Z*T]K/N<3RK!-W]FCM;OXI>([F()$;2U8-G?##DD>GSEAC\.U8.J>*
M-;UE2E_J4\L94*T0(1& .1E5P"<]R.P]*R**ESD]V;4L#AJ3O"FD_37[PHHH
MJ3J"BBB@ KT;X9^$_M<Z:_=_ZF!R+>)D^^X'W^1C )XQ_$.VWG.\#^!Y/$$J
MW]^K1Z6C<#H;@CL/1?4_@.<D>TQ11PQ)%$BQQHH5$08"@= !V%=-"E?WF?,Y
MYFRA%X:B_>>[[>7K^0^BBBNP^-"BBB@ HHHH **** "BBB@#Q#XDZ%_9/B1K
MN)<6VH9F7GI)_&.I/4ANP^; Z5QM>X_$V.V?P5<-.5\Q)8V@RV"7W8.!W.TO
MQ]3VKPZO/K149Z'Z%DF)EB,(G+>.GK;_ ( 4445D>L%;W@[0O^$A\26]HZYM
MD_?7'/\ RS7&1U!Y)"\<C.>U8->R_"_P_P#V?HSZK/'BYO?]7N7E8ATZC(W'
MGJ00%-:4H<TK'FYMB_JN%E-/WGHO5_Y;G>4445Z)^<A1110 4444 %%%% !1
M110 4444 %%%% !7*>)/ .DZ^KRQHME?,VXW$2<-R2=RY 8G)YZ].<<5U=%*
M45)69M0Q%6A/GI2LSY\UWP=K7A[+W=MOMA_R\P$O'VZGJO) ^8#)Z9K!KZAK
ME-4^'7AS4V+BU:SD+ EK1M@( QC:05 ^@'3ZURSPW\I]1A.)(VY<3'YK_+^O
M0\)HKNM4^%>MVC$V$D%_'N 4!A&^,<DAC@#/'#'M^'*:AHFJ:5N-_I]S;J'\
MO?)&0A;G@-T/0]#S7/*$H[H^@H8W#U_X4T_S^[<H4445)U!1110 4444 %%%
M;.G^$]?U3:;72KEE9/,5Y%\M&7C!#-@'KV--)O8BI5A35YM)>>AC45Z3HWPF
MN96636;Q88RH/DVQW/D@Y!8C (..F[//UKO]'\*Z+H21_8K&/SDY%Q( TI.,
M$[CR,CL,#D\<UM'#R>^AXN*S_"T=*?OORV^__*YY/X?^'6L:RS/=(VFVZ-M+
M7$3!V.,_*AQD=.21UXS@BO6M$\,Z3X?BVZ?:*LA7:\[_ #2/TSEO0X!P,#/:
MM>BNJ%*,-CY?'9KB,6[2=H]E_6H4445H>8%%%% !1110 4R6*.:)XI462-U*
MNCC(8'J".XI]% 7L>1>*?AE<V;27FAAKFW+%C:_QQ+C/RDGYQU&/O=/O<FO/
M98I(97BE1HY$8JZ.,%2.H([&OI^LC6_#.D^((MNH6BM(%VI.GRR)UQAO09)P
M<C/:N:>'3UB?2X'B*=-*&(7,N_7_ ()\ZT5WFL?"S5[6>1]+,=Y;%\1H9 DH
M7&?FSA>.G!YZX';D-1TG4=)E\O4+*>V8LRJ9$(#$==IZ,.G(SU%<LH2CNCZG
M#XW#XA?NII^77[MRE1114G4%%%% !114MM;7%Y.L%K!)/,^=L<2%F.!DX YZ
M4";25V145U>E_#KQ'J:AS:K9QE20UVVPD@XQM + _4#I]*]&\._#K2=#ECNI
MF:^O8VW)+(-J(1G!5/7D=2>0",5K"C.1Y>+SG"X=/WN9]E_GLCS;P_X"UK7O
M+F\K[)9M@^?."-R\'*KU;@Y!X!QUKV?1M"T[0+);:PMUC&T!Y"!OE(SRS=SR
M?IGC K2HKKITHPV/C\?FM?&Z2TCV7Z]PHHHK4\P**** "BBB@ HHHH ****
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MN?"\08SVV(]E':'Y]?\ (****W/!"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** ,:Y\)>'KJ!H9-&LE5L9,4(C;KGAEP1^!K&O/AAX;N=GD
MQ7-IMSGR)B=WUW[NGMCK7945+A%[HZJ>.Q-/X*C7S9P?_"I=!_Y^]2_[^)_\
M11_PJ70?^?O4O^_B?_$5WE%3[*'8W_M;&_\ /QG!_P#"I=!_Y^]2_P"_B?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7!_%#Q!_9^C)I4$F+F]_P!9M;E8AUZ'(W'CH00&%=Y7SOXJUAM=\27E[YOF
M0[RD!&0!&O"X!Y&1R1ZD\5C7GRQMW/;R+!K$8GGEM#7Y]/\ /Y&-1117 ?>A
M1174> O#_P#;WB2+SH]UG:XFGRN5;'W4/!!R>QZ@-3BG)V1E7K1H4I59[(];
M\':%_P (]X;M[1UQ<O\ OKCG_EHV,CJ1P %XX.,]ZWJ**]-))61^85JLJU1U
M)[O4****9F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 <;\2==_LGPVUI$V+G4,PKQTC_C/0CH
M0O8_-D=*\0KIO'FMQZYXIGE@*M;VZBWB=?XPI.6R"006+8([8KF:\^M/FD?H
MF3X3ZMA8IKWGJ_Z\D%%%%9'J!7N/PWT9M*\+1SRJHGOF\\D*,A"!L!(/(Q\W
MMN(QUKRKPCHRZ]XFL[*16:WW&2?"DC8HR02", \+G/&X5]"UU8:&O,?+<28R
MT8X:/75_H%%%%=9\@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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*BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
